B9A Stock Chart & Stats
€29.28
€1.74(6.24%)
At close: 4:00 PM EDT
€29.28
€1.74(6.24%)
Day’s Range― - ―
52-Week Range€23.92 - €34.96
Previous CloseN/A
Volume10.00
Average Volume (3M)27.00
Market Cap
€2.46B
Enterprise Value€27.31B
Total Cash (Recent Filing)€1.99B
Total Debt (Recent Filing)€90.61M
Price to Earnings (P/E)259.0
Beta0.40
Next Earnings
Nov 25, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.19
Shares Outstanding74,344,690
10 Day Avg. Volume0
30 Day Avg. Volume27
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)13.99
Price to Sales (P/S)13.76
P/FCF Ratio19.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.28
Revenue Forecast (FY)€139.01M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits financial risk and reduces the burden of interest or refinancing obligations. A strong equity base gives BioArctic greater flexibility to continue research, support partnered programs, and absorb earnings fluctuations without relying heavily on additional debt.
Strong ProfitabilityThe current margin and profitability profile indicates that BioArctic can generate meaningful earnings from its business activities. Strong gross and operating profitability can provide internal funding for innovation while improving resilience during periods of uneven revenue or development timing.
Partner-funded ModelBioArctic’s partnering model allows larger pharmaceutical companies to finance substantial development, regulatory, and commercialization activities. This can reduce the company’s need to build a large sales organization or fund the full late-stage cost burden internally, supporting capital efficiency.
Bears Say
Revenue ContractionA sharp decline in the revenue run-rate weakens near-term visibility into the company’s recurring earning base. Because partnering revenue can depend on milestones and collaboration timing, sustained contraction would make it harder to plan investment and demonstrate consistent commercial progress.
Volatile Cash GenerationAlthough current cash generation remains positive, the large year-to-year swings show that cash conversion is not yet dependable. Periods of negative operating and free cash flow could constrain internally funded research and increase reliance on partnership receipts or other financing sources.
Earnings VolatilityThe pronounced swings in annual profitability make BioArctic’s earnings power less predictable than that of a mature business. Such variability can complicate resource allocation, obscure underlying operating trends, and leave results sensitive to the timing of partnerships, milestones, or development activities.
BioArctic AB Class B News
B9A FAQ
What was BioArctic AB Class B’s price range in the past 12 months?
BioArctic AB Class B lowest stock price was €23.92 and its highest was €34.96 in the past 12 months.
What is BioArctic AB Class B’s market cap?
BioArctic AB Class B’s market cap is €2.46B.
When is BioArctic AB Class B’s upcoming earnings report date?
BioArctic AB Class B’s upcoming earnings report date is Nov 25, 2026 which is in 29 days.
How were BioArctic AB Class B’s earnings last quarter?
BioArctic AB Class B released its earnings results on Aug 26, 2026. The company reported -€0.012 earnings per share for the quarter, beating the consensus estimate of -€0.03 by €0.018.
Is BioArctic AB Class B overvalued?
According to Wall Street analysts BioArctic AB Class B’s price is currently Overvalued.
Does BioArctic AB Class B pay dividends?
BioArctic AB Class B does not currently pay dividends.
What is BioArctic AB Class B’s EPS estimate?
BioArctic AB Class B’s EPS estimate is 0.02.
How many shares outstanding does BioArctic AB Class B have?
BioArctic AB Class B has 74,344,690 shares outstanding.
What happened to BioArctic AB Class B’s price movement after its last earnings report?
BioArctic AB Class B reported an EPS of -€0.012 in its last earnings report, beating expectations of -€0.03. Following the earnings report the stock price went up 4.606%.
Which hedge fund is a major shareholder of BioArctic AB Class B?
Currently, no hedge funds are holding shares in DE:B9A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioArctic AB Class B
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Technical Analysis
BioInvent International AB
―
Alzinova AB
―
AlzeCure Pharma AB
―
Saniona AB
―
IRLAB Therapeutics AB Class A
―